Produced
in partnership with The Society for
Cardiac Angiography and Interventions
www.scai.org
You will need:
Course ID: AB0149
Live Web e-debate:
Drug-Eluting Stents:
Will Cost Constraints Affect Their Wide Use?
This event was recorded on:
Thursday, February 20 2003
Supported by an unrestricted educational grant from:
Additional information/content from the American College of Cardiology Foundation on Drug Eluting Stents is available on the DES Clinical Collection on Cardiosource.com.
|
Powered by
|
The Protagonist:
Jeffrey W. Moses, MD, FACC, FSCAI
Chief, Interventional Cardiology
Lenox Hill Interventional Cardiology
New York, NY
Disclosures: Consultant, Common Stockholder:
Cordis (Johnson & Johnson)
The Antagonist:
Ron Waksman, MD, FACC
Clinical Professor of Medicine
Director, Experimental Angioplasty and Vascular Brachytherapy
Cardiovascular Research Institute
Washington Hospital Center, Washington, DC
Disclosures: Consultant: Nucletron, Guidant,
Radiance; royalties: Emory/Novosta
Moderator:
Joseph D. Babb, MD, FACC, FSCAI
Professor of Medicine
East Carolina University School of Medicine
Director, Cardiac Catheterization Laboratories
Pitt County Memorial Hospital
Disclosures: None
Overview
Course length: 1 hour 20 minutes
Healthcare providers find themselves in a constant tug-of-war between providing quality care and managing costs. This struggle is often greatest during the introduction of new technologies. It is predicted that by 2005, the use of these stents could reduce surgery by almost 50%, cause significant reductions of medical therapy, and increase the frequency of intervention procedures for coronary artery disease. Although the use of drug-eluting stents brings promise of improved outcomes for cardiology patients, it also poses an economic impact. For example, cardiologists must be aware of the high cost of these devices and the impact of their use on the patient's financial and medical insurance resources.
Learning Objectives
Upon completion of this course, you will be able to:
- Discuss the potential impact of drug-eluting stents
- Understand the costs associated with drug-eluting stents
- Based on evidence-based research data, determine if drug-eluting stents
are appropriate for your patient
Learner Participation to Earn Credit
To earn a CME certificate, you must:
Computer Requirements to Participate
Click here to view the computer requirements to participate in this activity.
Target Audience
This CME activity is beneficial for any healthcare practitioner or administrator who will be involved in the decision to use drug-eluting stents.
Accreditation Period
This activity was approved for AMA category 1 credit
for two years from the original release date of February 20, 2003. After
February 20, 2005 it will no longer be certified for credit, but may still
have value for the healthcare provider.
Accreditation Statement
Continuing Medical Education for Physicians
This activity has been planned and implemented in accordance with the
Essential Areas and Policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of The Society
for Cardiac Angiography and Interventions (SCAI) and CEU-Online. The SCAI
is accredited by the ACCME to provide continuing medical education for
physicians.
The Society for Cardiac Angiography and Interventions designates this educational activity for a maximum of 1.5 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only the credit that he/she actually spent in the activity.
Questions Regarding This Event
Please click here to e-mail any questions you have regarding this activity.
As an organization accredited for continuing medical education (CME), SCAI fully complies with the legal requirements of the Americans with Disabilities Act rules and regulations. If any participant is in need of accommodations, written requests should be submitted as soon as possible.
Course Certificate Fees
This course certificate is FREE to all qualified participants.